Royalty Pharma plc Share-based Payment Arrangement, Expense
Royalty Pharma plc (RPRX) reported Share-based Payment Arrangement, Expense of $107.36 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-05
- Royalty Pharma plc share-based payment arrangement, expense for the quarter ending 2026-06-30 was $107.36M, a 17.92% increase year-over-year.
- Royalty Pharma plc share-based payment arrangement, expense for the quarter ending 2026-03-31 was $122.29M, a 17295.73% increase year-over-year.
- Royalty Pharma plc share-based payment arrangement, expense for the quarter ending 2025-12-31 was $125.79M, a 17542.50% increase year-over-year.
- Royalty Pharma plc share-based payment arrangement, expense for the quarter ending 2025-09-30 was $73.35M, a 10187.94% increase year-over-year.
- Royalty Pharma plc share-based payment arrangement, expense for fiscal 2025 was $290.89M, a 8922.64% increase from fiscal 2024.
- Royalty Pharma plc share-based payment arrangement, expense for fiscal 2024 was $3.22M, a 2.36% decline from fiscal 2023.
- Royalty Pharma plc share-based payment arrangement, expense for fiscal 2023 was $3.30M.
- Royalty Pharma plc share-based payment arrangement, expense for fiscal 2021 was $3.10M, a 45.61% decline from fiscal 2020.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $107.36M 10-Q · filed 2026-08-05 | $229.65M 10-Q · filed 2026-08-05 | $355.44M derived: sum of 3 quarters · filed 2026-08-05 | $428.79M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $122.29M 10-Q · filed 2026-05-06 | $248.08M derived: sum of 2 quarters · filed 2026-05-06 | $321.44M derived: sum of 3 quarters · filed 2026-05-06 | $412.48M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $125.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $199.14M derived: sum of 2 quarters · filed 2026-02-11 | $290.19M derived: sum of 3 quarters · filed 2026-08-05 | $290.89M 10-K · filed 2026-02-11 |
| 2025-09-30 | $73.35M 10-Q · filed 2025-11-05 | $164.40M derived: sum of 2 quarters · filed 2026-08-05 | $165.10M 10-Q · filed 2025-11-05 | $165.81M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $91.04M 10-Q · filed 2026-08-05 | $91.75M 10-Q · filed 2026-08-05 | $92.46M derived: sum of 3 quarters · filed 2026-08-05 | $93.17M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $703.00K 10-Q · filed 2026-05-06 | $1.42M derived: sum of 2 quarters · filed 2026-05-06 | $2.13M derived: sum of 3 quarters · filed 2026-05-06 | |
| 2024-12-31 | $713.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $1.43M derived: sum of 2 quarters · filed 2026-02-11 | $3.22M 10-K · filed 2026-02-11 | |
| 2024-09-30 | $713.00K 10-Q · filed 2025-11-05 | $2.51M 10-Q · filed 2025-11-05 | ||
| 2023-12-31 | $3.30M 10-K · filed 2026-02-11 | |||
| 2022-03-31 | $700.00K 10-Q · filed 2022-05-05 | $1.40M derived: sum of 2 quarters · filed 2022-05-05 | $2.10M derived: sum of 3 quarters · filed 2022-05-05 | $3.00M derived: sum of 4 quarters · filed 2022-05-05 |
| 2021-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $1.40M derived: sum of 2 quarters · filed 2022-02-15 | $2.30M derived: sum of 3 quarters · filed 2022-02-15 | $3.10M 10-K · filed 2022-02-15 |
| 2021-09-30 | $700.00K 10-Q · filed 2021-11-10 | $1.60M derived: sum of 2 quarters · filed 2021-11-10 | $2.40M 10-Q · filed 2021-11-10 | $3.50M derived: sum of 4 quarters · filed 2022-05-05 |
| 2021-06-30 | $900.00K 10-Q · filed 2021-08-11 | $1.70M 10-Q · filed 2021-08-11 | $2.80M derived: sum of 3 quarters · filed 2022-05-05 | $3.80M derived: sum of 4 quarters · filed 2022-05-05 |
| 2021-03-31 | $900.00K 10-Q · filed 2022-05-05 | $1.90M derived: sum of 2 quarters · filed 2022-05-05 | $2.90M derived: sum of 3 quarters · filed 2022-05-05 | $6.60M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $2.00M derived: sum of 2 quarters · filed 2022-02-15 | $5.70M derived: sum of 3 quarters · filed 2022-02-15 | $5.70M 10-K · filed 2022-02-15 |
| 2020-09-30 | $1.00M 10-Q · filed 2021-11-10 | $4.70M derived: sum of 2 quarters · filed 2021-11-10 | $4.70M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $3.70M 10-Q · filed 2021-08-11 | $3.70M 10-Q · filed 2021-08-11 | ||
| 2020-06-17 | $0.00 10-K · filed 2022-02-15 | |||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-12 | $0.00 10-Q · filed 2020-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |